Sex Differences in Risk of Severe Adverse Events in Patients Receiving Immunotherapy, Targeted Therapy, or Chemotherapy in Cancer Clinical Trials.
Joseph M UngerRiha VaidyaKathy S AlbainMichael LeBlancLori M MinasianCarolyn C GotayNorah L HenryMichael Jordan FischShing M LeeCharles D BlankeDawn L HershmanPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
The greater severity of both symptomatic AEs and hematologic AEs in women across multiple treatment modalities indicates that broad-based sex differences exist. This could be due to differences in AE reported, pharmacogenomics of drug metabolism/disposition, total dose received, and/or adherence to therapy. Particularly large sex differences were observed for patients receiving immunotherapy, suggesting that studying AEs from these agents is a priority.
Keyphrases
- clinical trial
- papillary thyroid
- polycystic ovary syndrome
- adverse drug
- early onset
- squamous cell
- drug induced
- type diabetes
- randomized controlled trial
- emergency department
- pregnancy outcomes
- phase ii
- weight loss
- mesenchymal stem cells
- metabolic syndrome
- glycemic control
- young adults
- adipose tissue
- bone marrow
- rectal cancer